RxDoctor Payments Data

Mohammad Abdul Waheed, MD

Interventional Cardiology · Bowling Green, KYNPI 1790996080

Payments from drug & device makers

$9,504in general payments, 2019–2025

Across 353 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$2K
  • Novartis$720
  • Abiomed$606
  • GE HealthCare$435
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$383
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$2,89630%
  • Food & beverage$6,59469%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,504 in reported general payments places this provider in the 45th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$217,658
Medicare patients
1,082
Services billed
2,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban593$608,998
BrilintaTicagrelor260$191,455
EntrestoSacubitril/Valsartan153$188,063
XareltoRivaroxaban185$180,934
JardianceEmpagliflozin54$54,627
FarxigaDapagliflozin Propanediol35$35,403
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,525
VascepaIcosapent Ethyl21$7,935
Atorvastatin Calcium1,111$7,702
Metoprolol Succinate535$6,647
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,136
Dofetilide40$5,082
ClopidogrelClopidogrel Bisulfate521$4,540
Ranolazine ErRanolazine63$4,338
Losartan Potassium467$3,700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$309$608,998593 claims
AstraZenecaBrilinta, Farxiga$334$226,858295 claims
NovartisEntresto$720$188,063153 claims
Johnson & JohnsonXarelto$137$180,934185 claims
Boehringer IngelheimJardiance$14$54,62754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →